Top 10 Companies in the (R)-1-(2-Methoxyphenyl)-ethylamine (CAS 68285-23-4) Market (2026): Market Leaders Powering Global Pharmaceutical Innovation

In Business Insights
November 16, 2026

MARKET INSIGHTS

The Global (R)-1-(2-Methoxyphenyl)-ethylamine (CAS 68285-23-4) market was valued at USD 28.4 million in 2025. Forecast figures indicate a rise to USD 30.1 million in 2026 and an expansion to USD 52.7 million by 2034, reflecting a steady CAGR of 7.3% across the period.

(R)-1-(2-Methoxyphenyl)-ethylamine is a chiral amine that features an ethylamine backbone with a 2‑methoxyphenyl side chain in the (R) configuration. Its optical activity makes it indispensable as a resolving agent and as a building block for pharmaceutical intermediates, particularly those targeting cardiovascular and central nervous system indications.

Demand for enantiomerically pure intermediates has become a defining trend in the pharmaceutical sector, driving the need for high‑purity chiral building blocks. Investments in chiral chemistry research and a regulatory focus on single‑enantiomer drugs reinforce this momentum. Advancements in asymmetric synthesis techniques and an uptick in activity among contract research and manufacturing organizations (CROs and CMOs) are broadening the application scope of this amine. Leading suppliers—TCI Chemicals, Sigma‑Aldrich (Merck KGaA), and Alfa Aesar—continue to provide high‑optical‑purity grades to meet stringent industry requirements.

(R)-1-(2-Methoxyphenyl)-ethylamine (CAS 68285-23-4) Market – View in Detailed Research Report

TOP 10 COMPANIES IN THE MARKET

  1. Hairui Chemical Co., Ltd. (China)
    Headquarters: Shenzhen, China
    Key Offering: Large‑scale production of pharmaceutical‑grade (R)-1-(2‑methoxyphenyl)-ethylamine with >99% enantiomeric excess
    Hairui Chemical has invested heavily in continuous‑flow chiral resolution technologies, enabling high‑throughput manufacturing that meets global pharmacopeia standards. The company’s focus on process optimisation and stringent quality controls has positioned it as a preferred supplier for major API developers seeking reliable, high‑purity intermediates.

    • Advanced continuous‑flow chiral resolution
    • Strict compliance with FDA, EMA, and REACH guidelines
    • Strategic partnerships with leading CROs for custom synthesis
  2. Biosynth AG (Switzerland)
    Headquarters: Zürich, Switzerland
    Key Offering: cGMP‑compliant, high‑purity chiral intermediates for R&D and clinical pipelines

    Biosynth AG leverages its Carbosynth acquisition to deliver small‑batch, high‑purity chiral amines with rapid turnaround. The firm’s emphasis on traceability and low impurity levels appeals to biotech firms that require stringent validation for early‑stage drug discovery.

    • Custom synthesis for niche applications
    • Strong focus on analytical verification and batch consistency
    • Rapid scale‑up capabilities for emerging APIs
  3. PharmaBlock Sciences Co., Ltd. (China)
    Headquarters: Shanghai, China
    Key Offering: Multi‑ton production of (R)-1-(2‑methoxyphenyl)-ethylamine with integrated chiral resolution and downstream purification

    PharmaBlock Sciences has expanded its manufacturing footprint to include state‑of‑the‑art hydrogenation and chromatographic systems, allowing the company to deliver consistent enantiomeric purity across large volumes. Its production strategy aligns with the growing demand for high‑quality intermediates in the Asia‑Pacific region.

    • High‑throughput production lines
    • Optimised hydrogenation protocols for cost efficiency
    • Robust supply chain integration with raw‑material suppliers
  4. Enamine Ltd. (Ukraine)
    Headquarters: Kyiv, Ukraine
    Key Offering: Advanced chiral resolution technologies and small‑batch production for academic and industrial research

    Enamine’s portfolio includes a range of chiral amines tailored for asymmetric synthesis. The firm’s small‑batch flexibility and emphasis on purity make it a go‑to partner for laboratories and contract manufacturers seeking bespoke solutions.

    • Flexible batch sizes for R&D projects
    • High optical purity with rigorous analytical support
    • Collaborations with academic institutions for pilot‑scale studies
  5. SynQuest Laboratories, Inc. (USA)
    Headquarters: San Diego, California, USA
    Key Offering: Custom synthesis of chiral intermediates with a focus on stereoselective processes

    SynQuest Laboratories combines expertise in stereoselective synthesis with a portfolio of chiral amines. The company’s capabilities in catalyst development and process scale‑up support the needs of pharmaceutical companies seeking efficient routes to enantiopure APIs.

    • Stochastic catalyst optimisation
    • Scale‑up support for early‑stage development
    • Integration of green chemistry principles
  6. Apollo Scientific Ltd. (UK)
    Headquarters: London, United Kingdom
    Key Offering: High‑purity chiral intermediates with a focus on regulatory compliance for clinical trials

    Apollo Scientific delivers chiral amines that meet cGMP standards, providing pharmaceutical developers with reliable materials for phase I‑III studies. The firm’s emphasis on quality assurance and documentation supports its position as a trusted supplier in the European market.

    • Comprehensive QC and documentation services
    • Rapid batch release for clinical timelines
    • Support for regulatory submissions
  7. Capot Chemical Co., Ltd. (China)
    Headquarters: Guangzhou, China
    Key Offering: Chiral amine production with integrated downstream processing

    Capot Chemical focuses on efficient downstream processing to reduce solvent usage and improve overall yields. The company’s commitment to green chemistry aligns with the ESG priorities of many pharmaceutical clients.

    • Solvent‑reduction strategies
    • Process intensification for cost savings
    • Alignment with sustainability goals
  8. Matrix Scientific (USA)
    Headquarters: Austin, Texas, USA
    Key Offering: Custom chiral synthesis for niche therapeutic areas

    Matrix Scientific provides bespoke chiral synthesis solutions for emerging therapeutic modalities, including peptide and small‑molecule drugs. Their expertise in catalyst development enables efficient routes to high‑purity intermediates.

    • Custom catalyst design
    • Rapid prototyping for new APIs
    • Support for early‑stage development
  9. Oakwood Products, Inc. (USA)
    Headquarters: Cincinnati, Ohio, USA
    Key Offering: High‑purity chiral intermediates with a focus on industrial‑grade applications

    Oakwood Products delivers chiral amines suitable for both pharmaceutical and agrochemical applications. Their production lines emphasize scalability and cost efficiency while maintaining stringent purity standards.

    • Industrial‑scale production capacity
    • Cost‑effective purification processes
    • Broad application portfolio
  10. TCI Chemicals (Japan)
    Headquarters: Tokyo, Japan
    Key Offering: Broad portfolio of fine chemicals with a focus on chiral intermediates

    TCI Chemicals supplies a range of chiral amines that meet global pharmacopeia standards. Their distribution network spans Asia, Europe, and North America, ensuring timely delivery to clients worldwide.

    • Extensive distribution network
    • High‑purity product catalog
    • Support for regulatory compliance

Download FREE Sample Report: View Sample Report

Get Full Report Here: View Full Report

OUTLOOK & FORECAST

From 2026 to 2034, the market is projected to grow from USD 30.1 million to USD 52.7 million, reflecting a stable CAGR of 7.3%. The expansion is underpinned by a steady increase in the pipeline of cardiovascular and CNS therapeutics, alongside a rising emphasis on single‑enantiomer drugs across major regulatory jurisdictions. The Asia‑Pacific region will continue to dominate production capacity, driven by cost advantages and expanding contract manufacturing services.

FUTURE TRENDS

  • Adoption of biocatalytic resolution methods is accelerating, offering lower solvent footprints and higher enantiomeric excess.
  • Integration of digital supply‑chain platforms is improving visibility and reducing lead times for chiral intermediates.
  • Emerging agrochemical applications for chiral pesticides and herbicides are creating new demand streams.
  • Investment in green chemistry initiatives is expected to cut production costs by up to 20% for leading manufacturers.